Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $26 | $6 | $4 | $1 |
| % Growth | 371.7% | 23.1% | 443.6% | – |
| Cost of Goods Sold | $0 | $35 | $20 | $14 |
| Gross Profit | $0 | -$30 | -$16 | -$14 |
| % Margin | 0% | -535.7% | -347.4% | -1,655% |
| R&D Expenses | $51 | $35 | $20 | $14 |
| G&A Expenses | $0 | $7 | $8 | $8 |
| SG&A Expenses | $37 | $7 | $8 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $6 | $0 | $0 | $0 |
| Operating Expenses | $93 | $7 | $8 | $8 |
| Operating Income | -$67 | -$37 | -$24 | -$22 |
| % Margin | -259.6% | -670.8% | -532.5% | -2,623% |
| Other Income/Exp. Net | $4 | $0 | $1 | -$1 |
| Pre-Tax Income | -$64 | -$37 | -$23 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$64 | -$37 | -$23 | -$22 |
| % Margin | -245.1% | -670.2% | -517.5% | -2,695.1% |
| EPS | -2.36 | -1.08 | -0.96 | -1.35 |
| % Growth | -118.5% | -12.5% | 28.9% | – |
| EPS Diluted | -2.36 | -1.08 | -0.96 | -1.35 |
| Weighted Avg Shares Out | 27 | 34 | 24 | 16 |
| Weighted Avg Shares Out Dil | 27 | 34 | 24 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $0 | $1 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$67 | -$36 | -$23 | -$20 |
| % Margin | -259.6% | -654.6% | -506.3% | -2,487.6% |